TD Cowen analyst Yaron Werber initiates coverage on $UpStream Bio (UPB.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 57.9% and a total average return of 14.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $UpStream Bio (UPB.US)$'s main analysts recently are as follows:
Upstream Bio's primary asset, verekitug, is a recombinant human IgG1 monoclonal antibody designed to target the thymic stromal lymphopoietin receptor, which is intended for the treatment of severe asthma, chronic rhinosinusinitis with nasal polyps, and COPD. Analysts view verekitug as the central catalyst for the company's stock performance over the medium to long term as its clinical profile continues to develop.
The initiation of coverage on Upstream Bio highlighted the company's verekitug as a 'differentiated fast follower' that potentially offers greater potency and more extended dosing intervals in comparison to Tezspire. The Phase 1 data revealed 'rapid, deep, and sustained effects' on asthma biomarkers.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
TD Cowen分析師Yaron Werber首次給予$UpStream Bio (UPB.US)$買入評級。
根據TipRanks數據顯示，該分析師近一年總勝率為57.9%，總平均回報率為14.1%。
此外，綜合報道，$UpStream Bio (UPB.US)$近期主要分析師觀點如下：
Upstream Bio的主要資產verecltug是一種重組人IgG1單克隆抗體，旨在靶向胸腺基質淋巴細胞生成素受體，用於治療嚴重哮喘、慢性鼻竇炎伴鼻息肉和阻塞性肺疾病。分析師認爲verecltug作爲該公司股票表現在中長期的中心催化劑，其臨床資料不斷髮展。
對Upstream Bio的覆蓋初始化突出了公司的verecltug作爲一個「不同凡響的快速跟隨者」，其潛在提供比Tezspire更大的效力和更長的用藥間隔。第1期數據顯示在哮喘生物標誌物上產生了「迅速、深刻且持久的效果」。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
